Anti-GPCR Antibody Production Service

The G protein-coupled receptor family is a class of seven-transmembrane proteins and one of the most important target families in medicine. A large share of therapeutic drugs act through these receptors, and compounds that cannot reach a GPCR on their own can still show pharmacological activity when guided to the receptor by a targeting molecule. As antibody technology has matured — and as GPCR production and purification have improved — antibody-mediated targeting of these receptors has become an increasingly practical option.

Among the formats that have drawn attention are the heavy-chain antibodies found in camelids such as camels and alpacas. Their antigen-binding region, a single-domain antibody, combines a small size with monoclonal-like properties: the low molecular weight means low steric hindrance and low production cost, while the single binding domain retains high affinity and specificity. Together these traits make single-domain antibodies attractive as guide molecules for receptor-directed drugs. Yet generating anti-GPCR antibodies remains genuinely difficult, so we draw on several routes for multi-transmembrane targets — soluble-domain design, recombinant protein immunization, and whole-cell immunization — and match the route to the receptor, aiming to obtain the best-quality antibody at the lowest experimental risk.

What the Service Covers

• Target and route selection – assessing the receptor and choosing the preparation route most likely to succeed.
• Soluble-domain design – building constructs from accessible regions of the receptor where a useful epitope can be presented.
• Recombinant immunization – producing and immunizing with a defined receptor construct.
• Whole-cell immunization – presenting the receptor in its membrane context when conformation is decisive.
• Antibody and fragment formats – including single-domain formats suited to receptor-directed work.
• Screening and validation – testing candidates against the receptor in the intended application.

Why GPCRs Are Difficult to Target

Antibody Formats for GPCR Work

• Conventional antibodies – full-size immunoglobulins where a standard reagent is required.
• Single-domain antibodies – compact binders derived from camelid heavy-chain antibodies, offering low steric hindrance and low production cost with high affinity and specificity.
• Receptor-directed fragments – smaller formats useful where access to a confined site matters.

Workflow

• Assess the receptor – define the target and its accessible regions.
• Select the route and format – choose soluble-domain, recombinant, or whole-cell preparation and the antibody format.
• Prepare the immunogen – build and verify the chosen antigen form.
• Immunize and screen – raise the response and select receptor-specific candidates.
• Validate and deliver – confirm performance and supply the antibody with data.

Applications

• Receptor research – reagents for studying GPCR biology and signaling.
• Receptor-directed therapeutics – binders used to guide or modulate drugs acting at a GPCR.
• Structural and biochemical studies – antibodies supporting receptor analysis.
• Assay development – receptor-specific reagents for detection and screening workflows.

Why Work With Us

GPCRs punish an inflexible approach: a route that works for one receptor may fail for the next. We begin by assessing the receptor, then select among soluble-domain design, recombinant immunization, whole-cell immunization, and compact single-domain formats to fit the target rather than forcing the target to fit a single method. The aim is the best-quality antibody at the lowest experimental risk, matched to the receptor you are working on.